纳米制剂的药代动力学建模：概念、实施与挑战。

Pharmacokinetic Modeling in Nano-formulations: Concept, Implementation and Challenges.

机构信息

Translational Medicine & Clinical Pharmacology, Boehringer-Ingelheim Pharmaceutical, Inc. Ridgefield, CT 06877, United States.

Clinical Pharmacology, Early Clinical Development, Pfizer, Inc., Cambridge, MA 02139, United States.

出版信息

Curr Pharm Des. 2018;24(43):5175-5180. doi: 10.2174/1381612825666190130141310.

DOI:10.2174/1381612825666190130141310

PMID:30706804

Abstract

The properties of nanoparticles can be exploited to overcome challenges in drug delivery. By virtue of its design and size, the pharmacokinetics of nanoparticles are different than other small molecules. Modeling and simulation techniques have great potential to be used in nanoformulation development; however, their use in optimization of nanoformulation is very limited. This review highlights the differences in absorption, distribution, metabolism and excretion (ADME) characteristics of nanoparticles, use of modeling and simulation techniques in nanoformulation development and challenges in the implementation of modeling techniques.

摘要

纳米粒子的特性可被利用来克服药物传递中的挑战。由于其设计和大小，纳米粒子的药代动力学与其他小分子不同。建模和模拟技术在纳米制剂开发中有很大的应用潜力；然而，它们在纳米制剂优化中的应用非常有限。本文重点介绍了纳米粒子的吸收、分布、代谢和排泄（ADME）特征的差异，以及建模和模拟技术在纳米制剂开发中的应用和建模技术实施中的挑战。